Cleo Opens a New Ovarian Cancer Screening Opportunity
3 min read
9:09am on Thursday 24th of September, 2026 AEST ~9am, 24th Sept, 26
Cleo Diagnostics has begun developing a multi-biomarker blood test for ovarian cancer screening in asymptomatic women, targeting a stated $150 billion global market. The prototype program will run alongside the company’s pre-surgical test, with initial proof-of-concept data expected early next quarter.
- Prototype screening test development has commenced
- Stated $150 billion global population-screening opportunity
- Initial proof-of-concept cohort will include 250 patients
- General screening target requires 75% sensitivity and 99.6% specificity
- FDA 510(k) submission for pre-surgical test remains targeted for H1 CY2027
Cleo Diagnostics Limited (ASX:COV) is opening a second, much larger front in ovarian cancer diagnostics, beginning prototype development of a blood test intended to detect early-stage disease in asymptomatic women. The company puts the potential global population-screening market at $150 billion, although the project remains at the prototype and early evaluation stage.
Screening Program Runs Alongside Pre-Surgical Test
The screening work will proceed as a separate development stream while Cleo keeps its pre-surgical ovarian cancer test as the primary commercial and regulatory focus. That product remains targeted for FDA 510(k) submission in the first half of calendar 2027, meaning the new program does not change the company’s stated near-term route towards the US market.
Cleo says the screening test will use its existing biomarker technology, clinical datasets and development infrastructure. The company also points to access to two screening biobanks: the UK Collaborative Trial of Ovarian Cancer Screening collection through University College London, and the US Prostate, Lung, Colorectal and Ovarian biobank. Those resources are intended to provide representative populations for future development and evaluation, according to the announcement.
High Specificity Bar Set for General Population
The technical hurdle is materially different from pre-surgical triage because ovarian cancer is less prevalent among asymptomatic women. Cleo has set minimum targets of 90% sensitivity and 90% specificity for high-risk screening, while general population screening carries a higher specificity target of 99.6% alongside 75% minimum sensitivity.
That 99.6% specificity threshold matters because a screening test used across a low-prevalence population can generate substantial numbers of false positives even when its sensitivity is strong. Cleo says the targets are based on predictive probabilities relevant to clinical use, including positive and negative predictive values. They are company-defined performance requirements, not results demonstrated by the program to date.
The first step is a 250-patient proof-of-concept study enriched for Stage I ovarian cancers. Cleo expects initial screening data early next quarter and is targeting completion of the test panel architecture by the end of calendar 2026. Further bridging and confirmation studies would then expand the cohort before evaluation in prospectively collected high-risk and general-population groups.
The immediate test for the strategy is therefore not the size of the addressable market but whether the prototype can approach the demanding performance thresholds in appropriately representative samples. The next data release should provide the first indication of whether Cleo’s screening ambition is supported by measurable test performance, while the separate FDA pathway remains the nearer-term milestone.
Bottom Line?
Cleo has widened its long-term opportunity, but the investment case still turns first on early proof-of-concept performance and progress towards the separate H1 CY2027 FDA submission.
Questions in the middle?
- Will the 250-patient proof-of-concept cohort support the company’s proposed sensitivity and specificity thresholds?
- Can Cleo finalise the screening panel architecture by the end of CY2026 without diverting focus from the pre-surgical test?
- How will performance translate from an enriched Stage I cohort to prospective general-population screening?
